Galapagos N.V.(0JXZ)
EUR --+0.00%
Reward45Moderate
Risk9Low
50%Data
Strong 60% profit margin · Revenue down 82% YoY
0JXZ
+0.0 · +0.00%
EUR · LSE
Galapagos N.V. |
Earnings Deterioration
Market Cap:3.87Bn
ⓘ
Reward Rating
45
Moderate
Reward Assessment
50% data coverage
Bottom 25% of stocksView factors
ⓘ
Risk Rating
9
Low
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0JXZ to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for 0JXZ, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Galapagos N.V.?

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.

0JXZ · Verdict

Moderate reward · low risk

0JXZ stands out on cash flow and volatility, but watch the growth signal.

Based on 75% data coverage

0JXZ · Verdict

What’s working & what to watch

Strengths 3

  • Cash flow95/100

    Top decile vs peers

  • Volatility95/100

    Top decile vs peers

  • Balance sheet92/100

    Current ratio 8.11

Watchouts 1

  • Growth34/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Galapagos N.V.?

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company is listed on the LSE in UK, with a market capitalisation of 3.87B.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (45)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
IndustryN/A
Market Cap3.87B
P/E RatioN/A
Dividend YieldN/A
Beta0.112
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.